Transchem (500422)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what Transchem is not: a going pharma concern. In the latest quarter, sales are ₹0 Cr. A business with no revenue has no pricing power, no moat, no economic engine. The -100% sales growth and -61.87% profit decline confirm this is not a growth story. The market cap is ₹48 Cr, yet book value is ₹68.39 per share; on the surface, a price-to-book of 0.56 appears cheap. But value investing is about buying assets that produce future earnings, not just balance sheet numbers. With ROE of only 3.79% and ROCE of 9.11%, this equity is earning very little. The P/E of 77.14 is absurd for a company with shrinking profits; it simply reflects a tiny profit base, not healthy earnings power. The Piotroski F-Score of 3/9 also flags weak financial health. There is no dividend, so shareholders are not being paid to wait. The 52-week range, from ₹214.80 down to ₹38.45, tells me Mr. Market has soured on this story, and the zero-sales quarter suggests he may be right. As Graham would say, price is what you pay, value is what you get. Here, the book value provides a possible floor, but only if the assets are genuine, liquid, and honestly carried. Without sales, what is the company actually doing? The ₹1 Cr net profit in the latest quarter smells like interest or other income, not operating strength. This may be a cigar-butt asset play, but you must demand a margin of safety given the poor fundamentals. I would wait for clarity on asset quality and any plan to revive operations before acting.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer